Cidara Therapeutics (CDTX) Q1 2025 earnings summary

Executive summary

• CD388, a novel long-acting antiviral drug-Fc conjugate for universal influenza prevention, is the exclusive development focus after divesting rezafungin assets in April 2024.

• CD388 demonstrated strong preclinical and clinical efficacy, including activity against resistant and high-pathogenicity flu strains, and is designed for once-per-season dosing.

• The Phase 2b NAVIGATE trial completed enrollment and dosing of 5,041 subjects across three dose levels and placebo, with data cutoff on April 30, 2025, and top-line results expected by late June 2025.

• Regulatory discussions with the FDA are ongoing, potentially impacting statistical analysis and Phase 3 dose selection due to the severe 2024-2025 flu season.

• Leadership promotions were announced in May 2025 to support clinical and regulatory strategy.

Financial highlights

• Cash, cash equivalents, and restricted cash totaled $174.5 million as of March 31, 2025, down from $196.2 million at year-end 2024.

• Net loss from continuing operations was $23.5 million for Q1 2025, compared to $8.2 million in Q1 2024.

• R&D expenses increased to $24.6 million in Q1 2025 from $5.9 million in Q1 2024, mainly due to the NAVIGATE study and higher personnel costs.

• G&A expenses rose to $6.2 million from $3.6 million year-over-year, primarily due to higher personnel costs.

• No collaboration revenue recognized in Q1 2025; $1.0 million recognized in Q1 2024 from Janssen.

Outlook and guidance

• Top-line results from the NAVIGATE Phase 2b trial are anticipated by late June 2025, with final PK and safety data expected in September.

• Phase 3 study initiation is targeted for spring 2026, focusing on high-risk and immune-compromised patients, pending Phase 2b results.

• Cash on hand is expected to fund operations for at least one year from the reporting date; additional funding will be needed to advance CD388 beyond Phase 2b.